
ABOUT ROOSTERBIO
RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid commercialization of scalable regenerative cures. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year.
RoosterBio is driven by our client's success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.
FEATURED ARTICLES
-
Learn about one path forward to navigate the pitfalls with mRNA transfection and a medium to assist in lentivirus-mediated transduction of human mesenchymal stromal/stem cells (hMSCs).
-
Learn about new data that highlights exciting uses for future immunotherapy studies.
-
Learn more about plausible benefits of AAV’s use in concert with hMSCs, and how a complete genetic engineering medium was expanded beyond lentivirus.
-
Learn how to incorporate standardized cell banks & right-scaled processes into your experimental design for rapid implementation & robust, reproducible results.
-
Learn more about a system that fuels the rapid commercialization of scalable regenerative cures.
-
Explore some of the questions and theories behind why, after compelling pre-clinical and human safety data, MSC therapeutics are not progressing faster.
-
Read through the results of our efforts to produce an optimal protocol for the transient transfection of hMSCs with pDNA or mRNA using non-viral means.
-
See the results of our study to scale-up of a Xeno-Free (XF) fed batch microcarrier-based process for hMSC expansion in stirred tank reactors to the 50L scale.
-
We look into the signs that regenerative medicine can less afford FBS as high-quality sources become scarcer and how “cultivators” of hMSCs and other cells transition to a new, future-facing tradition.
-
This work establishes an optimized genetic modification unit operation within the context of a scalable xeno-free manufacturing process to reproducibly generate populations of genetically modified hMSCs.
-
Industry experts discuss developing functionally enhanced hMSCs as living bioreactors to serve as the next generation in bio-responsive drug delivery.
-
Regardless of your favorite nomenclature for adipose tissue-derived hMSCs (hAD-MSCs, MSC(AT),AT-MSCs), there really is more beneath their story than meets the eye.
-
Discover how we successfully developed and optimized a process to maximize hMSC yield using microcarriers in a stirred tank bioreactor system.
-
Learn why allogeneic MSCs could be a favorable option in comparison with autologous MSCs.
-
Discover how our microcarrier-based technology harvests hMSCs while showing high proliferation capacity, expression of hMSC-specific markers, significant trilineage differentiation potential, and strong immunomodulatory and angiogenic potency.
-
In this blog, discover feasible strategies to maximize the number of hMSC-EVs generated by the upstream process and how to make well-engineered hMSC-EVs a thriving therapeutic modality.
-
We discuss critical process parameters that may be utilized to control for CQAs in 3D bioreactor systems and the comparability of CQAs and functional attributes between hMSCs manufactured in 2D planar culture vs. 3D bioreactor culture.
-
We explore how T cells and MSCs don’t have to compete for program time and resources—but can instead work together quite nicely!
-
Biopharmaceuticals need to scale up from laboratory to commercial production at a key point in their development and thus need clearly defined process economics to achieve critical velocity toward commercial success.
-
We discuss the importance of building a strong cost model with a step-by-step MSC-based example and illustrate how your model can positively impact your product and process development.
CONTACT INFORMATION
RoosterBio
5295 Westview Drive Suite 275
Frederick, MD 21703
UNITED STATES
Phone: 240-831-4914
RESOURCES
-
When MSCs are genome-edited, it will inevitably be done with cell therapy in mind and should involve complementary breakthroughs to scale up and industrialize gene delivery.
BROCHURES
- RoosterGEM™ - A Complete Genetic Engineering Medium
- RoosterVial™ MSCs
- RoosterNourish™ Mesenchymal Stromal Cell (MSC) Expansion Media
- RoosterCollect™ Exosome/Extracellular Vesicle Production
- RoosterReplenish™ hMSC Bioreactor Feed
- RoosterBio Process Development Services
- RoosterCollect EV Pro™ - Extracellular Vesicle (EV) Production